Ironwood Pharmaceuticals (IRWD) Return on Capital Employed (2011 - 2026)

Ironwood Pharmaceuticals has disclosed Return on Capital Employed across 16 years of filings, most recently posting 64.87% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 64.87%, up 4665.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 64.87% (up 4665.0% YoY), and the FY2025 annual result was 11.17%, down 1386.0% from the prior year.
• Return on Capital Employed came in at 64.87% for Q1 2026 at Ironwood Pharmaceuticals, up from 9.53% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 97.0% in Q3 2025 to a low of 491.1% in Q1 2024.
• The 5-year median for Return on Capital Employed is 5.7% (2022), against an average of 66.22%.
• Across the five-year window, Return on Capital Employed slumped 49611 bps in 2024 and soared 50932 bps in 2025, its largest moves.
• Ironwood Pharmaceuticals' Return on Capital Employed stood at 5.07% in 2022, then sank by 8515 bps to 426.89% in 2023, then soared by 107 bps to 28.1% in 2024, then tumbled by 66 bps to 9.53% in 2025, then surged by 580 bps to 64.87% in 2026.
• The last three Return on Capital Employed figures came in at 64.87% (Q1 2026), 9.53% (Q4 2025), and 97.0% (Q3 2025), per Business Quant data.